Regulation of D2 and D3 receptors in transfected cells by agonists and antagonists.
Burris
K D
KD
CNS Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA.
Fausing
S M
SM
Molinoff
P B
PB
D000067956:Adenylyl Cyclase Inhibitors; D001921:Brain / Q000378:metabolism; D002460:Cell Line; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D017448:Receptors, Dopamine D2 / Q000096:biosynthesis* / Q000187:drug effects; D050637:Receptors, Dopamine D3; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000187:drug effects; D012457:Salicylamides / Q000494:pharmacology; D013469:Sulpiride / Q000494:pharmacology; D014162:Transfection; D015854:Up-Regulation / Q000187:drug effects; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D000067956:Adenylyl Cyclase Inhibitors; C493593:DRD3 protein, human; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D011994:Recombinant Proteins; D012457:Salicylamides; D010566:Virulence Factors, Bordetella; D013469:Sulpiride; D019204:GTP-Binding Proteins; D006220:Haloperidol; C045989:eticlopride